#1 Clinical Trials Search in Europe

Jk08

JK08, a novel recombinant fusion protein, is currently undergoing clinical trials for patients with unresectable locally advanced or metastatic cancer. This groundbreaking study aims to evaluate the safety, effectiveness, and potential of JK08 in treating various types of solid tumors. The trial involves both monotherapy and combination treatments, offering hope for patients with difficult-to-treat cancers.

Table of Contents

What is JK08?

JK08 is a new medication being studied for the treatment of various advanced and metastatic cancers. It is classified as a recombinant fusion protein, which means it’s a specially engineered protein made up of different parts to serve a specific purpose in fighting cancer[1].

How JK08 Works

JK08 is designed to work in two main ways to help your immune system fight cancer:

  1. Targeting CTLA-4: One part of JK08 is a human antibody that targets a protein called CTLA-4. CTLA-4 normally helps prevent your immune system from becoming overactive. By blocking CTLA-4, JK08 may help your immune system recognize and attack cancer cells more effectively.
  2. Using IL-15: Another part of JK08 includes a protein complex involving IL-15, which is a substance that can stimulate certain immune cells to grow and become more active in fighting cancer.

This dual approach is intended to boost your immune system’s ability to find and destroy cancer cells throughout your body[1].

Cancers Targeted by JK08

JK08 is being studied to treat a wide range of advanced or metastatic cancers. These include:

  • Solid tumors: These are cancers that form solid masses in organs or tissues.
  • Colorectal cancer: Cancer that starts in the colon or rectum.
  • Lung cancers: Both non-small cell and small-cell lung cancers.
  • Urothelial carcinoma: A type of bladder cancer.
  • Head and neck cancer: Specifically, squamous cell carcinoma in these areas.
  • Breast cancer: Including both luminal (hormone receptor-positive) and triple-negative types.
  • Kidney cancers: Clear cell and papillary renal cell carcinomas.
  • Gastric and gastroesophageal cancers: Cancers of the stomach and where the stomach meets the esophagus.
  • Skin cancer: Specifically, squamous cell carcinoma of the skin.
  • Pancreatic cancer: Specifically, pancreatic adenocarcinoma.
  • Liver cancer: Specifically, hepatocellular carcinoma.
  • Ovarian cancer: Specifically, epithelial ovarian cancer.

This wide range of cancers suggests that JK08 may have broad potential in treating various types of advanced or metastatic cancers[1].

Clinical Trial Overview

JK08 is currently being studied in a Phase 1/2 clinical trial. This means it’s in the early stages of testing in humans. The trial is designed to:

  1. Evaluate safety: Researchers will closely monitor how well patients tolerate JK08 and what side effects may occur.
  2. Determine the right dose: The study will test different doses to find the safest and most effective amount to give patients.
  3. Assess how the drug works in the body: This includes studying how JK08 is processed by the body (pharmacokinetics) and how it affects the immune system (pharmacodynamics).
  4. Look for signs of effectiveness: While it’s early in the testing process, researchers will be watching for any indications that JK08 is helping to fight cancer[1].

Treatment Administration

In the clinical trial, JK08 is given as a subcutaneous injection. This means it’s injected just under the skin, similar to how some diabetes medications are given. The current plan is to administer JK08 once a week, with three doses given over a 21-day treatment cycle[1].

Combination Therapies

The study is also looking at how JK08 might work when combined with other cancer treatments:

  • Pembrolizumab: This is another type of immunotherapy that works by targeting a different immune checkpoint called PD-1. It’s being tested in combination with JK08 for non-small cell lung cancer and colorectal cancer.
  • Lenvatinib: This is a targeted therapy that works by blocking certain proteins involved in cancer growth. It’s being tested with JK08 for liver cancer (hepatocellular carcinoma)[1].

Safety and Effectiveness Measures

The researchers will be closely monitoring several aspects of JK08’s performance:

  • Safety: They’ll track any side effects or serious reactions that occur during treatment.
  • Tumor response: They’ll measure if tumors shrink or stop growing in response to JK08.
  • Survival: They’ll look at how long patients live without their cancer getting worse (progression-free survival) and overall survival time.
  • Disease control: They’ll assess how many patients have their cancer stop growing or shrink for a meaningful period of time[1].

It’s important to remember that JK08 is still in the early stages of testing. While it shows promise, more research is needed to fully understand its safety and effectiveness in treating cancer.

Aspect Details
Drug Name JK08
Drug Type Recombinant fusion protein targeting CTLA-4 and IL-15
Administration Subcutaneous injection, once weekly
Trial Phase Phase 1/2
Target Conditions Unresectable locally advanced or metastatic solid tumors
Combination Therapies Pembrolizumab, Lenvatinib
Primary Outcomes Safety, tolerability, dose-limiting toxicity, maximum-tolerated dose
Secondary Outcomes Pharmacokinetics, objective response rate, disease control rate, progression-free survival, overall survival

FAQ

  • What is JK08 and how does it work? JK08 is a recombinant fusion protein that combines two functional elements: a human monoclonal antibody targeting CTLA-4 and a protein complex formed by human IL-15 and the Sushi domain of human IL-15Rα. It is designed to enhance the immune system's ability to fight cancer cells.
  • What types of cancer are being studied in the JK08 clinical trial? The trial is studying JK08 in various advanced solid tumors and metastatic cancers, including colorectal cancer, non-small cell lung cancer, small-cell lung cancer, urothelial carcinoma, head and neck cancer, breast cancer, renal cell carcinoma, gastric cancer, skin cancer, pancreatic cancer, and hepatocellular carcinoma.
  • How is JK08 administered to patients in the trial? JK08 is administered as a subcutaneous injection (an injection under the skin) on a once-weekly schedule. The treatment cycle is defined as 21 days, during which three doses of JK08 are planned for administration.
  • Are there any combination therapies being tested with JK08? Yes, the trial includes combination therapies. JK08 is being tested in combination with Pembrolizumab for non-small cell lung cancer and colorectal cancer, and with Lenvatinib for hepatocellular cancer.
  • What are the main outcomes being measured in this clinical trial? The main outcomes being measured include dose-limiting toxicity, maximum-tolerated dose, safety and tolerability, pharmacokinetics of JK08, objective response rate, disease control rate, progression-free survival, and overall survival.

Ongoing Clinical Trials on Jk08

  • Study of JK08, Pembrolizumab, and Lenvatinib for Patients with Advanced or Metastatic Cancer

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Spain

Glossary

  • Recombinant fusion protein: A protein created in a laboratory by combining parts of different proteins to achieve a specific function.
  • CTLA-4: A protein that helps regulate the immune system's response to cancer cells.
  • IL-15: A protein that stimulates the growth and activity of certain immune cells.
  • Subcutaneous injection: An injection given under the skin.
  • Dose-limiting toxicity (DLT): Side effects that are severe enough to prevent increasing the dose of a drug in a clinical trial.
  • Maximum-tolerated dose (MTD): The highest dose of a drug that can be given without causing unacceptable side effects.
  • Pharmacokinetics: The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and excreted.
  • Objective response rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Disease control rate (DCR): The percentage of patients whose cancer shrinks, disappears, or remains stable after treatment.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with cancer without it getting worse.
  • Overall survival (OS): The length of time from the start of treatment that patients are still alive.

References